Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals

Cancer Immunology, Immunotherapy

Volumn 56, Issue 8, 2007, Pages 1183-1192

  Godefroy, Emmanuelle ^a   Wang, Yu ^a   Souleimanian, Naira E ^a   Scotto, Luigi ^a   Stevanovic, Stefan ^b   Chen, Yao Tseng ^c   Valmori, Danila ^a   Ayyoub, Maha ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Human; T lymphocytes; Tumor immunity

Indexed keywords

ANTIGEN; EPITOPE; SYNOVIAL SARCOMA X BREAKPOINT ANTIGEN 1; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN PURIFICATION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DONOR; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NORMAL HUMAN; PEPTIDE ANALYSIS; PREDICTION; PRIORITY JOURNAL;

ADULT; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; REFERENCE VALUES; REPRESSOR PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS;

EID: 34248586073     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0269-9     Document Type: Article

References (30)

1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32
2. Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jäger E, Knuth A, Pfreundschuh M, Old LJ, Chen YT (1997) SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 72:965-971
3. dos Santos NR, de Bruijn DR, Balemans M, Janssen B, Gartner F, Lopes JM, de Leeuw B, Geurts van Kessel A (1997) Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum Mol Genet 6:1549-1558
4. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, Rauscher FJ 3rd (1994) Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA 91:4509-4513
5. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP, Schaffner W (1996) Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res 24:4859-4867
6. Sandberg AA, Bridge JA (2002) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 133:1-23
7. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7:502-508
8. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, Larsson O (1999) A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 91:974-975
9. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, Minami A, Hiraga H, Nishihara H, Sawa H, Nagashima K (2001) Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 98:3843-3848
10. Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, Lundeberg J, Uhlen M, Larsson O (1999) The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 59:3180-3184
11. Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N, Larsson O (2002) SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 62:3861-3867
12. Xie Y, Tornkvist M, Aalto Y, Nilsson G, Girnita L, Nagy B, Knuutila S, Larsson O (2003) Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 22:7628-7631
13. + T cells are selectively expanded during immune responses to antigen expressing tumors in melanoma patients. Cancer Res 63:5601-5606
14. + T cells in association with HLA-DR. J Clin Invest 113:1225-1233
15. + T cell responses to SSX-4 in melanoma patients. J Immunol 174:5092-5099
16. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS, Sheu JC (2001) Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 164:189-195
17. Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D (2003) SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun 3:13
18. Naka N, Araki N, Nakanishi H, Itoh K, Mano M, Ishiguro S, de Bruijn DR, Myoui A, Ueda T, Yoshikawa H (2002) Expression of SSX genes in human osteosarcomas. Int J Cancer 98:640-642
19. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219
21. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
22. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384
23. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684-693
24. Scott AM, Welt S (1997) Antibody-based immunological therapies. Curr Opin Immunol 9:717-722
25. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854
26. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200-205
27. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T (2005) Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23:9008-9021
28. Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P, Cerottini JC, Hesdorffer CS, Old LJ, Valmori D (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813-1822
29. + T cells in cancer-free individuals. Clin Immunol 117:161-167
30. + T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol [Epub ahead of print]